Start with a free account for 3 free CME credits. Already a subscriber? Sign in.

Paper Chase #3 | Effect of Pip-Tazo vs Meropenem in Bacteremia

Steve Biederman, MD and Tom Robertson, MD
00:00
05:58
Sign in or subscribe to listen

No me gusta!

The flash player was unable to start. If you have a flash blocker then try unblocking the flash content - it should be visible below.

BOTTOM LINE: Among patients with E coli or K pneumoniae bloodstream infection and ceftriaxone resistance, definitive treatment with piperacillin-tazobactam compared with meropenem did not result in a noninferior 30-day mortality. These findings do not support use of piperacillin-tazobactam in this setting.

To view chapter written summaries, you need to subscribe.

Sign up today for full access to all episodes.

To join the conversation, you need to subscribe.

Sign up today for full access to all episodes and to join the conversation.

To download files, you need to subscribe.

Sign up today for full access to all episodes.
Hello, New Year! Bye Bye, PPIs? Full episode audio for MD edition 201:19 min - 94 MB - M4APC RAP January 2019 Written Summary 386 KB - PDF

To earn CME for this chapter, you need to subscribe.

Sign up today for full access to all episodes and earn CME.

0.25 Free AMA PRA Category 1 Credits™ certified by Hippo Education or 0.25 Free prescribed credits by the American Academy of Family Physicians

  1. Complete Quiz
  2. Complete Evaluation
  3. Print Certificate

3.25 AMA PRA Category 1 Credits™ certified by Hippo Education or 3.25 prescribed credits by the American Academy of Family Physicians

  1. Complete Quiz
  2. Complete Evaluation
  3. Print Certificate